Malaysian Genomics Resource Centre Bhd (XKLS:0155) Accounts Receivable: RM2.56 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKLS:0155 Malaysian Genomics Resource Centre Bhd XKLS:0155
47 GF Score
Price RM0.37
GF Value RM0.31
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Malaysian Genomics Resource Centre Bhd Accounts Receivable?

Malaysian Genomics Resource Centre Bhd XKLS:0155 47 Accounts Receivable is RM2.56 Mil as of Jun. 2026. GuruFocus rates XKLS:0155 with a GF Score™ of 47/100 and a GF Value™ of RM0.31 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Malaysian Genomics Resource Centre Bhd's accounts receivables for the quarter that ended in Jun. 2026 was RM2.56 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Malaysian Genomics Resource Centre Bhd's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 91.68.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Malaysian Genomics Resource Centre Bhd's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was RM0.03.


Malaysian Genomics Resource Centre Bhd Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Malaysian Genomics Resource Centre Bhd's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=2.562/2.55*91
=91.68

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Malaysian Genomics Resource Centre Bhd's accounts receivable are only considered to be worth 75% of book value:

Malaysian Genomics Resource Centre Bhd's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(4.307+0.75 * 2.562+0.5 * 0.771-3.091
-0--1.11)/150.931
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Malaysian Genomics Resource Centre Bhd Accounts Receivable Related Terms


Malaysian Genomics Resource Centre Bhd Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Malaysian Genomics Resource Centre Bhd's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malaysian Genomics Resource Centre Bhd Accounts Receivable Chart

Malaysian Genomics Resource Centre Bhd Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec24 Dec25
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 3.38 9.11 4.33 2.60

Malaysian Genomics Resource Centre Bhd Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.33 9.26 2.60 8.12 2.56
XKLS:0155
47GF Score
Malaysian Genomics Resource Centre Bhd XKLS:0155
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Malaysian Genomics Resource Centre Bhd Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of RM2.56 Mil mean?
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a Accounts Receivable of RM2.56 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors.
Is Malaysian Genomics Resource Centre Bhd's Accounts Receivable too high?
Malaysian Genomics Resource Centre Bhd's current Accounts Receivable is RM2.56 Mil. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's Accounts Receivable compare to TMO and DHR?
Malaysian Genomics Resource Centre Bhd's Accounts Receivable of RM2.56 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Diagnostics & Research company?
A good Accounts Receivable depends on the Medical Diagnostics & Research industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. Malaysian Genomics Resource Centre Bhd's current Accounts Receivable is RM2.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.31, compared to a current price of RM0.37 — trading 17.7% above its estimated fair value. The current Accounts Receivable is RM2.56 Mil. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current Accounts Receivable is RM2.56 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?

Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be overvalued. The current stock price of RM0.37 is trading 17.7% above its estimated GF Value™ of RM0.31. GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Modestly Overvalued.

Key valuation signals for XKLS:0155:

  • Accounts Receivable: RM2.56 Mil
  • GF Value™: RM0.31 vs. price of RM0.37 (17.7% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Malaysian Genomics Resource Centre Bhd Business Description

Address Jalan Teknologi 3/6, 8F, Taman Sains Selangor 1, Kota Damansara (PJU5), Petaling Jaya, SGR, MYS, 47810
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
47GF Score

Get the complete analysis for XKLS:0155

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.37
Price
RM0.31
GF Value